Literature DB >> 23795181

Cardiovascular risk: Are all NSAIDs alike?

Nadia Pawlosky1.   

Abstract

Year:  2013        PMID： 23795181      PMCID： PMC3676195          DOI： 10.1177/1715163513481569

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN： 1715-1635


× No keyword cloud information.
  10 in total

Review 1.  An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.

Authors:  Michael E Farkouh; Bruce P Greenberg
Journal:  Am J Cardiol       Date:  2009-05-01       Impact factor: 2.778

2.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

3.  Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome.

Authors:  Héctor Bueno; Alfredo Bardají; Paola Patrignani; Elisa Martín-Merino; Luis A García-Rodríguez
Journal:  Am J Cardiol       Date:  2010-02-20       Impact factor: 2.778

4.  Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs.

Authors:  Shelley R Salpeter; Peter Gregor; Thomas M Ormiston; Richard Whitlock; Parminder Raina; Lehana Thabane; Eric J Topol
Journal:  Am J Med       Date:  2006-07       Impact factor: 4.965

5.  Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study.

Authors:  Angel Lanas; Jesús Tornero; José Luis Zamorano
Journal:  Ann Rheum Dis       Date:  2010-05-24       Impact factor: 19.103

Review 6.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.

Authors:  Sven Trelle; Stephan Reichenbach; Simon Wandel; Pius Hildebrand; Beatrice Tschannen; Peter M Villiger; Matthias Egger; Peter Jüni
Journal:  BMJ       Date:  2011-01-11

7.  Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.

Authors:  A Rostom; P Moayyedi; R Hunt
Journal:  Aliment Pharmacol Ther       Date:  2008-11-27       Impact factor: 8.171

8.  Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Authors:  David J Kerr; Janet A Dunn; Michael J Langman; Justine L Smith; Rachel S J Midgley; Andrew Stanley; Joanne C Stokes; Patrick Julier; Claire Iveson; Ravi Duvvuri; Christopher C McConkey
Journal:  N Engl J Med       Date:  2007-07-26       Impact factor: 91.245

9.  Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

Authors:  Scott D Solomon; Janet Wittes; Peter V Finn; Robert Fowler; Jaye Viner; Monica M Bertagnolli; Nadir Arber; Bernard Levin; Curtis L Meinert; Barbara Martin; Joseph L Pater; Paul E Goss; Peter Lance; Stefanie Obara; Emily Y Chew; Jonghyeon Kim; Gretchen Arndt; Ernest Hawk
Journal:  Circulation       Date:  2008-03-31       Impact factor: 29.690

10.  Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.

Authors:  Wayne A Ray; Cristina Varas-Lorenzo; Cecilia P Chung; Jordi Castellsague; Katherine T Murray; C Michael Stein; James R Daugherty; Patrick G Arbogast; Luis A García-Rodríguez
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-05-05
  10 in total
  9 in total

Review 1.  Post-Craniotomy Pain Management: Beyond Opioids.

Authors:  Lauren K Dunn; Bhiken I Naik; Edward C Nemergut; Marcel E Durieux
Journal:  Curr Neurol Neurosci Rep       Date:  2016-10       Impact factor: 5.081

2.  Pretreatment of carprofen impaired initiation of inflammatory- and overlapping resolution response and promoted cardiorenal syndrome in heart failure.

Authors:  Veena Krishnan; David Booker; Gabrielle Cunningham; Jeevan Kumar Jadapalli; Vasundhara Kain; Amanda B Pullen; Ganesh V Halade
Journal:  Life Sci       Date:  2018-12-28       Impact factor: 5.037

Review 3.  Options for perioperative pain management in neurosurgery.

Authors:  Nalini Vadivelu; Alice M Kai; Daniel Tran; Gopal Kodumudi; Aron Legler; Eugenia Ayrian
Journal:  J Pain Res       Date:  2016-02-10       Impact factor: 3.133

4.  Cross-Sectional Study for Prevalence of Non-Steroidal Anti-Inflammatory Drug-Induced Gastrointestinal, Cardiac and Renal Complications in India: Interim Report.

Authors:  Suparna Chatterjee; Gur Prasad Dureja; Ganesh Kadhe; Amey Mane; Abhay A Phansalkar; Sandesh Sawant; Vaibhavi Kapatkar
Journal:  Gastroenterology Res       Date:  2015-07-22

5.  Retrospective Study of Reported Adverse Events Due to Complementary Health Products in Singapore From 2010 to 2016.

Authors:  Yimin Xu; Dhavalkumar N Patel; Suet-Leng P Ng; Siew-Har Tan; Dorothy Toh; Jalene Poh; Adena Theen Lim; Cheng-Leng Chan; Min-Yong Low; Hwee-Ling Koh
Journal:  Front Med (Lausanne)       Date:  2018-06-12

6.  Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project.

Authors:  Tania Schink; Bianca Kollhorst; Cristina Varas Lorenzo; Andrea Arfè; Ron Herings; Silvia Lucchi; Silvana Romio; René Schade; Martijn J Schuemie; Huub Straatman; Vera Valkhoff; Marco Villa; Miriam Sturkenboom; Edeltraut Garbe
Journal:  PLoS One       Date:  2018-09-19       Impact factor: 3.240

7.  Basic Pharmacological Characterization of EV-34, a New H2S-Releasing Ibuprofen Derivative.

Authors:  Alexandra Gyöngyösi; Vivien Verner; Ilona Bereczki; Attila Kiss-Szikszai; Rita Zilinyi; Árpád Tósaki; István Bak; Anikó Borbás; Pál Herczegh; István Lekli
Journal:  Molecules       Date:  2021-01-24       Impact factor: 4.411

8.  Top 10 most used drugs in the Kingdom of Saudi Arabia 2010-2015.

Authors:  Osama A AlKhamees; Khaled A AlNemer; Mohammed W Bin Maneea; Faisal A AlSugair; Bassam H AlEnizi; Adel A Alharf
Journal:  Saudi Pharm J       Date:  2017-12-15       Impact factor: 4.330

9.  NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain.

Authors:  Pierre Arsenault; Dan Chiche; William Brown; Jeffrey Miller; Roi Treister; Richard Leff; Philippe Walker; Nathaniel Katz
Journal:  Pain Rep       Date:  2018-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.